Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy

Xu, Jiabin; Cao, Wen‐Qiang; Wang, Penglai; Liu, Hong

doi:10.3390/ph15070876

Cited by 10 publications

(5 citation statements)

References 226 publications

(271 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NPs are one of the tools where trust is put on for achieving these goals. Tumor‐derived membrane NPs have demonstrated their effectiveness in eliciting strong immune responses against different cancer types (Mizrahy et al, 2017; Xu et al, 2022), making the design of tailored medicines for each patient possible. In the particular case of the skin, these NPs‐based treatments or preventive vaccines have been proved with positive outcomes against melanoma (Sainz et al, 2018; Silva et al, 2015), however, they were administered systemically or intratumorally (Mizrak et al, 2013).…”

Section: Summary and Prospects Of Nps@mapsmentioning

confidence: 99%

Microneedle‐assisted transdermal delivery of nanoparticles: Recent insights and prospects

Guillot

Martínez-Navarrete

Zinchuk-Mironova

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Transdermal delivery of drugs offers an interesting alternative for the administration of molecules that present certain troubles when delivered by the oral route. It can produce systemic effects or perform a local action when the formulation exerts an optimal controlled drug release or a targeted delivery to the specific cell type or site. It also avoids several inconveniences of the oral administration such as the hepatic first pass effect, gastric pH-induced hydrolysis, drug malabsorption because of certain diseases or surgeries, and unpleasant organoleptic properties. Nanomedicine and microneedle array patches (MAPs) are two of the trendiest delivery systems applied to transdermal research nowadays. However, the skin is a protective barrier and nanoparticles (NPs) cannot pass through the intact stratum corneum. The association of NPs and MAPs (NPs@MAPs) work synergistically, since MAPs assist NPs to bypass the outer skin layers, and NPs contribute to the system providing controlled drug release and targeted delivery. Vaccination and tailored therapies have been proposed as fields where both NPs and MAPs have great potential due to inherent characteristics. MAPs conception and easy use could allow selfadministration and therefore facilitate mass vaccination campaigns in undeveloped areas with weak healthcare services. Additionally, nanomedicine is being explored as a platform to personalize therapies in such an important field as oncology. In this work we show recent insights that prove the benefits of NPs@MAPs association and analyze the prospects and the discrete interest of the industry in NPs@MAPs, evaluating different limiting steps that restricts NPs@MAPs translation to the clinical practice.

show abstract

Section: Summary and Prospects Of Nps@mapsmentioning

confidence: 99%

Microneedle‐assisted transdermal delivery of nanoparticles: Recent insights and prospects

Guillot

Martínez-Navarrete

Zinchuk-Mironova

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…By utilizing the homologous targeting effect of tumor cell membranes, drugs can be effectively delivered to the gastric cancer region, which could serve as a paradigm for personalized therapies with the potential for clinical translation. [59,60]…”

Section: Ircb@m Biodistribution In Vivomentioning

confidence: 99%

Improved Photodynamic Therapy Based on Glutaminase Blockage via Tumor Membrane Coated CB‐839/IR‐780 Nanoparticles

Li,

et al. 2023

Small

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has promising applications. However, the lethal function of reactive oxygen species (ROS) produced during PDT is typically limited. This restriction is induced by oxygen shortage in the tumor microenvironment due to tumor cell hypermetabolism and reductive chemicals overexpression in tumor tissues. Glutamine (Gln) metabolism is crucial for malignancy development and is closely associated with redox. Herein, a novel nanoparticle (NP) named IRCB@M is constructed to boost PDT through dual effects. This NP simultaneously blocks aerobic respiration and inhibits cellular reduced substances by blocking the Gln metabolic pathway. Within the nanocomplex, a photosensitizer (IR‐780) and a glutaminase inhibitor (CB‐839) are self‐assembled and then encapsulated by cancer cell membranes for homologous targeting. The Gln metabolism intervention relieves hypoxia and decreases the levels of nicotinamide adenine dinucleotide phosphate (NADPH) as well as reduced glutathione (GSH) in vitro and in vivo, which are the dual amplification effects on the IR‐780‐mediated lethal PDT. The antitumor effects against gastric cancer are ultimately evoked in vivo, thus offering a novel concept for enhancing PDT and other ROS‐dependent therapeutic approaches.

show abstract

“… 9 , 10 They exhibit favorable stability, biocompatibility, extended blood circulation, and tumor tissue targeting, which can stimulate the immune system to induce specific immune responses. 11 , 12 , 13 , 14 EVs loaded with chemotherapeutic drugs are promising for novel drug delivery applications. Targeted delivery may increase the uptake of chemotherapeutic drug-loaded vesicles by cancer cells and improve their killing efficiency.…”

Section: Introductionmentioning

confidence: 99%

Tumor-derived extracellular vesicle drug delivery system for chemo-photothermal-immune combination cancer treatment

Bi,

Chen,

et al. 2024

iScience

View full text Add to dashboard Cite

Tumor-Derived Membrane Vesicles: A Promising Tool for Personalized Immunotherapy

Cited by 10 publications

References 226 publications

Microneedle‐assisted transdermal delivery of nanoparticles: Recent insights and prospects

Microneedle‐assisted transdermal delivery of nanoparticles: Recent insights and prospects

Improved Photodynamic Therapy Based on Glutaminase Blockage via Tumor Membrane Coated CB‐839/IR‐780 Nanoparticles

Tumor-derived extracellular vesicle drug delivery system for chemo-photothermal-immune combination cancer treatment

Contact Info

Product

Resources

About